Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells

Multiple myeloma (myeloma in short) is an incurable cancer of antibody-producing plasma cells that comprise 13% of all hematological malignancies. The proteasome inhibitor bortezomib has improved treatment significantly, but inherent and acquired resistance to the drug remains a problem. We here sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Starheim, K K, Holien, T, Misund, K, Johansson, I, Baranowska, K A, Sponaas, A-M, Hella, H, Buene, G, Waage, A, Sundan, A, Bjørkøy, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5141348/
https://www.ncbi.nlm.nih.gov/pubmed/27421095
http://dx.doi.org/10.1038/bcj.2016.56

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5141348/
https://www.ncbi.nlm.nih.gov/pubmed/27421095
http://dx.doi.org/10.1038/bcj.2016.56

Ejemplares similares